EG20726A - Process for preparing of galanthamine derivatives as acetylchol inc-sterase inhibitors - Google Patents

Process for preparing of galanthamine derivatives as acetylchol inc-sterase inhibitors

Info

Publication number
EG20726A
EG20726A EG64694A EG64694A EG20726A EG 20726 A EG20726 A EG 20726A EG 64694 A EG64694 A EG 64694A EG 64694 A EG64694 A EG 64694A EG 20726 A EG20726 A EG 20726A
Authority
EG
Egypt
Prior art keywords
acetylchol
preparing
compounds
galanthamine derivatives
sterase
Prior art date
Application number
EG64694A
Other languages
English (en)
Inventor
Raymond W Kosley Jr
Original Assignee
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc
Application granted granted Critical
Publication of EG20726A publication Critical patent/EG20726A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EG64694A 1993-10-15 1994-10-15 Process for preparing of galanthamine derivatives as acetylchol inc-sterase inhibitors EG20726A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/137,444 US6316439B1 (en) 1993-10-15 1993-10-15 Galanthamine derivatives as acetylcholinesterase inhibitors

Publications (1)

Publication Number Publication Date
EG20726A true EG20726A (en) 1999-12-29

Family

ID=22477461

Family Applications (1)

Application Number Title Priority Date Filing Date
EG64694A EG20726A (en) 1993-10-15 1994-10-15 Process for preparing of galanthamine derivatives as acetylchol inc-sterase inhibitors

Country Status (23)

Country Link
US (1) US6316439B1 (no)
EP (1) EP0649846B1 (no)
JP (1) JP2664343B2 (no)
KR (1) KR100227957B1 (no)
CN (1) CN1039910C (no)
AT (1) ATE211474T1 (no)
AU (1) AU696170B2 (no)
CA (1) CA2118172C (no)
CZ (1) CZ283731B6 (no)
DE (1) DE69429570T2 (no)
DK (1) DK0649846T3 (no)
EG (1) EG20726A (no)
ES (1) ES2170759T3 (no)
FI (1) FI108722B (no)
IL (1) IL111275A (no)
NO (1) NO307464B1 (no)
NZ (1) NZ264682A (no)
PL (1) PL177549B1 (no)
PT (1) PT649846E (no)
RO (1) RO114134B1 (no)
RU (1) RU2109743C1 (no)
TW (1) TW289754B (no)
ZA (1) ZA948061B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
AU780012B2 (en) * 1999-12-10 2005-02-24 Bonnie Davis Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
CN100343258C (zh) * 2001-04-30 2007-10-17 美国拜尔公司 新的4－氨基－5,6－取代的噻吩并[2,3－d]嘧啶化合物
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US20040254146A1 (en) * 2002-05-21 2004-12-16 Nastech Pharmaceutical Company Inc. Carboxylate salts of galantamine and their pharmaceutical use
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
WO2005065662A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
WO2005065661A2 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Immediate, controlled and sustained release formulations of galanthamine
EP1779867A4 (en) * 2004-07-01 2009-12-02 Eisai R&D Man Co Ltd MEANS FOR PROMOTING NERVE REVENERATION
EP1827468B1 (en) * 2004-12-23 2012-08-22 Curaxis Pharmaceutical Corporation Acetylcholinesterase Inhibitors and leuprolide acetate for the treatment of Alzheimer's disease
DE602006016441D1 (de) * 2005-05-13 2010-10-07 Alza Corp Mehrlagiges arzneimittelausbringsystem mit sperre gegen reservoirmaterialfluss
US20080188510A1 (en) * 2005-05-23 2008-08-07 Eisai R & D Management Co., Ltd. Novel methods using zonisamide
US20090253654A1 (en) 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
US20070104771A1 (en) * 2005-09-23 2007-05-10 Jay Audett Transdermal galantamine delivery system
EP2137192B8 (en) 2008-04-14 2014-06-11 Neurodyn Life Sciences Inc. Derivatives of galantamine as pro-drugs for the treatment of human brain diseases
CN102625700A (zh) * 2009-07-23 2012-08-01 夏尔有限责任公司 加兰他敏氨基酸和肽前药及其用途
EP3142669A2 (en) * 2014-05-16 2017-03-22 Synaptec Development LLC CLEARANCE OF AMYLOID ß
EP4029867A1 (en) 2021-01-13 2022-07-20 Alpha Cognition Inc. Solid forms of galantamine benzoate gluconate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL122665B1 (en) 1978-11-21 1982-08-31 Edinen Zentar Chim Process for preparing novel dienones of narvedine type and their derivatives
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
DE3856594D1 (de) * 1987-05-04 2008-11-27 Bonnie Davis Mittel zur behandlung der alzheimer-krankheit
NL8800350A (nl) 1988-02-12 1989-09-01 Stichting Biomedical Research Synthetische galanthamine-derivaten, werkwijze voor het bereiden daarvan, en farmaceutische samenstellingen.
EP0515301A3 (en) 1991-05-14 1993-06-16 Ernir Snorrason Improvements in benzodiazepine treatment by cholinesterterase inhibitors
US5153193A (en) 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs

Also Published As

Publication number Publication date
DE69429570T2 (de) 2002-08-29
ZA948061B (en) 1995-06-06
IL111275A0 (en) 1994-12-29
JPH07188239A (ja) 1995-07-25
PL305457A1 (en) 1995-04-18
PT649846E (pt) 2002-06-28
CA2118172A1 (en) 1995-04-16
FI944823A0 (fi) 1994-10-13
PL177549B1 (pl) 1999-12-31
IL111275A (en) 2003-01-12
CA2118172C (en) 2000-01-04
US6316439B1 (en) 2001-11-13
AU7581394A (en) 1995-05-04
FI108722B (fi) 2002-03-15
KR950011445A (ko) 1995-05-15
AU696170B2 (en) 1998-09-03
NO943895D0 (no) 1994-10-14
NO307464B1 (no) 2000-04-10
EP0649846B1 (en) 2002-01-02
JP2664343B2 (ja) 1997-10-15
EP0649846A1 (en) 1995-04-26
CN1039910C (zh) 1998-09-23
RO114134B1 (ro) 1999-01-29
ES2170759T3 (es) 2002-08-16
CZ254594A3 (en) 1995-07-12
FI944823A (fi) 1995-04-16
ATE211474T1 (de) 2002-01-15
CZ283731B6 (cs) 1998-06-17
TW289754B (no) 1996-11-01
RU2109743C1 (ru) 1998-04-27
DE69429570D1 (de) 2002-02-07
NO943895L (no) 1995-04-18
KR100227957B1 (ko) 1999-11-01
NZ264682A (en) 1995-07-26
RU94036745A (ru) 1996-12-10
CN1108657A (zh) 1995-09-20
DK0649846T3 (da) 2002-04-15

Similar Documents

Publication Publication Date Title
EG20726A (en) Process for preparing of galanthamine derivatives as acetylchol inc-sterase inhibitors
BG104998A (en) Isothiazole derivatives useful as anticancer agents
RU2088589C1 (en) Derivatives of 17 beta-substituted-4-aza-5-5 alpha-androstane-3-ones, methods of synthesis of compounds, pharmaceutical composition, compound 4
HUT70536A (en) Arylsulfonamido-substituted hydroxamic acids, process for preparing them and pharmaceutical compositions containing them
NZ225820A (en) Piperidyl substituted indole derivatives and pharmaceutical compositions
ZA896067B (en) Chemical compounds
HUT61555A (en) Process for producing 2,8-dioxa-bicyclo/3.2.1/octane derivatives and pharmaceutical compositions comprising same
EP0807633A3 (en) Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones
TW375615B (en) Galanthamine derivatives and their use as medicaments
ATE104145T1 (de) 4-substituierten imidazolen zur senkung des intraokularen druckes.
CA2252039A1 (en) Isatin derivatives as acetylcholinesterase inhibitors and analgesics
PL309874A1 (en) Novel derivatives of pyrrolocarbasol, method of obtaining them and pharmaceutical composition containing such derivatives
ES2019840A6 (es) Procedimiento para preparar nuevos derivados de tieno-triazolo-diazepina.
IL113780A (en) Glucopyranoside benzothiophenes process for their preparation and pharmaceutical compositions containing them
HUT70761A (en) Alkyl derivatives of trazodone having action for central nervous system, pharmaceutical compositions for preparing thereof
EP1057829A4 (en) Condensed pyrimidine derivatives and pharmaceutical compositions containing them
AU686104B2 (en) Substituted amidinonaphthyl ester derivatives
WO2000008006A3 (en) Piperidine and piperazine derivatives, process for their preparation and pharmaceutical compounds containing them
MXPA99003849A (es) Derivados 9a, 11b-deshidro de 9-oxima-3-ceto-6-0-metileritromicina.
MY103509A (en) Indole derivatives.